Outpace Bio
PrivateLast Round
Series B
Aug 1, 2024
Total Funding Raised
$174M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Outpace Bio operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series B round in August 2024.
Outpace Bio is a biotechnology company that develops AI-powered protein design technologies to engineer immune cells for more effective and safer cell therapies targeting solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Outpace Bio Comparables
Compare Outpace Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Evozyne | 83% | |
| ArsenalBio | 83% | |
| Profluent Bio | 80% |
For institutional investors. Book with your work email.
Outpace Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 1, 2024 | ||||
| Series A | Mar 31, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Outpace Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B |
| RA Capital Management | Series B |
| Gaingels | Series A |
| WRF Capital | Series A, Series B |
| Playground Global | Series A, Series B |
| ARTIS Ventures | Series B, Series A |
| Washington Research Foundation Capital | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 40% MoM.
- Nov 4, 2025
Lead candidate OPB-101 targeting ovarian cancer to begin dosing in 2025.
For institutional investors. Book with your work email.
Outpace Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Outpace Bio's valuation, stock price, and market status.
Is Outpace Bio a public or private company?
Outpace Bio is a private company.
What is the current stock price of Outpace Bio?
Outpace Bio is a private company, so its shares have no public market price. Caplight tracks Outpace Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Outpace Bio worth (valuation)?
Valuation information for Outpace Bio is not publicly available.
Can I buy Outpace Bio stock?
Outpace Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Outpace Bio's last funding round?
Outpace Bio's most recent funding round was Series B on August 1, 2024.
Who are the main investors in Outpace Bio?
Key investors in Outpace Bio include RA Capital Management, ARTIS Ventures.
Will Outpace Bio IPO soon?
No public IPO plans have been announced for Outpace Bio.
How can I track Outpace Bio secondary market activity?
Caplight tracks bids, offers, and trades in Outpace Bio's shares on secondary markets.